Today
+5.81%
5 Days
-18.02%
1 Month
-38.93%
6 Months
-86.87%
Year to Date
-95.52%
1 Year
-96.49%
Vivos Therapeutics (VVOS) Q2 2026 Earnings Call: Revenue Up 35%, Liquidity Risks Persist


| Shareholders | Proportion |
|---|---|
| V-CO Investors, L.L.C. | 9.87% |
| Skaff (Michael C.) | 9.79% |
| Luo (Dawei) | 4.17% |
| Armistice Capital LLC | 1.82% |
| Shareholder Types | Proportion |
|---|---|
| Individual Investor | 14.52% |
| Corporation | 11.54% |
| Investment Advisor | 2.63% |
| Hedge Fund | 1.85% |
Related Instruments